Status: Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Participants needed: 237
Trial details
Phase: Phase 3Age: 55+Biological sex: AllType: InterventionalSponsor: OcugenUpdated: Aug 19, 2026Locations: 3
Eligibility criteria
Subjects 55 years of age or older at consent. [+4]
Previous treatment with a gene-therapy or cell therapy product. [+4]